Spectral Medical (SD4) Price & Analysis

1 Followers

SD4 Stock Chart & Stats

€0.85

€0.01(1.19%)

At close: Jul 30 4:00 PM EDT

€0.85

€0.01(1.19%)

Day’s Range― - ―

52-Week Range€0.75 - €1.07

Previous CloseN/A

Volume0.00

Average Volume (3M)1.32K

Market Cap

€241.89M

Enterprise Value€411.25

Total Cash (Recent Filing)€803.00K

Total Debt (Recent Filing)€25.68M

Price to Earnings (P/E)―

Beta0.03

Next Earnings

Nov 06, 2026

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding293,554,000

10 Day Avg. Volume3,956

30 Day Avg. Volume1,318

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)-5.93

Price to Sales (P/S)169.36

P/FCF Ratio-42.55

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€2.17

Price Target Upside154.86% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.02

Revenue Forecast (FY)€1.74M

Bulls Say, Bears Say

Bulls Say

FDA PMA ProgressFDA acceptance reduces a major regulatory barrier for PMX and supports a future commercialization pathway. If approval is achieved, the milestone could materially expand access to Spectral’s lead therapy.

Clinical SupportSupportive follow-up data can strengthen the clinical case for PMX, improve credibility with regulators and providers, and support adoption. This is particularly important for a therapy used in high-risk critical-care settings.

Integrated PlatformCombining a targeted endotoxin-removal therapy with a diagnostic intended to identify suitable patients creates an integrated product strategy. This may improve clinical positioning and differentiate the platform if validation and approval succeed.

Bears Say

Balance Sheet StressNegative equity, rising debt, and a very small asset base leave little financial cushion against further losses. The resulting solvency risk may constrain investment, weaken negotiating leverage, and increase dependence on external funding.

Persistent Cash BurnSustained operating and free-cash-flow deficits indicate that current activities do not fund the business. Continued clinical, regulatory, and commercialization spending will likely require additional financing, creating dilution and execution risk.

Weak Commercial ScaleVery low and inconsistent revenue combined with deeply negative gross and net margins shows that the business has not reached sustainable commercial scale. The cost structure remains disproportionate to sales, limiting visibility toward break-even.

Spectral Medical News

Spectral Medical Hits Regulatory Milestone on PMX as Financing and Commercial Plans Advance

Spectral Medical ( ($TSE:EDT) ) has provided an update. Spectral Medical reported that the second quarter of 2026...

21d ago

EDTXF Upcoming Earnings Report: What to Expect?

Spectral Medical (Edtxf) (EDTXF) is scheduled to report 2nd quarter earnings on 08/07/2026. Regarding Q2 estimates, Wall Street...

23d ago

Spectral Medical Advances PMX Toward FDA Submission After Positive Tigris Results

Spectral Medical ( ($TSE:EDT) ) has shared an announcement. Spectral Medical reported its fourth quarter and full-year 2025...

5M ago

Spectral Medical’s Tigris Trial Shows Survival Benefit in Endotoxic Septic Shock

An announcement from Spectral Medical ( ($TSE:EDT) ) is now available. Spectral Medical and Vantive reported that full...

5M ago

Spectral Medical (Edtxf) (EDTXF) Q4 Earnings Cheat Sheet

Spectral Medical (Edtxf) (EDTXF) is scheduled to report 4th quarter earnings on 03/26/2026. Regarding Q4 estimates, Wall Street...

5M ago

Spectral Medical Pushes Back PMX-20R FDA Filing to Add 12-Month Mortality Data

Spectral Medical ( ($TSE:EDT) ) has shared an announcement. Spectral Medical has delayed the timing of its Premarket...

6M ago

Spectral Medical Reports Positive Trial Results and Revenue Growth

Spectral Medical (Edtxf) ( ($EDTXF) ) has released its Q3 earnings. Here is a breakdown of the information...

9M ago

Spectral Medical Reports Positive Tigris Trial Results and Prepares for FDA Submission

Spectral Medical ( ($TSE:EDT) ) has shared an update. Spectral Medical announced positive results from its Phase 3...

10M ago

Spectral Medical Files Base Shelf Prospectus to Raise $100 Million

Spectral Medical ( ($TSE:EDT) ) has issued an announcement. Spectral Medical Inc. has filed a final short form...

11M ago

Spectral Medical’s Study Highlights High-Risk Septic Shock Subgroup, Bolstering PMX Therapy Rationale

Spectral Medical ( ($TSE:EDT) ) has shared an update. Spectral Medical announced the publication of a study in...

12M ago

SD4 FAQ

What was Spectral Medical’s price range in the past 12 months?

Spectral Medical lowest stock price was €0.74 and its highest was €1.07 in the past 12 months.

What is Spectral Medical’s market cap?

Spectral Medical’s market cap is €241.89M.

When is Spectral Medical’s upcoming earnings report date?

Spectral Medical’s upcoming earnings report date is Nov 06, 2026 which is in 70 days.

How were Spectral Medical’s earnings last quarter?

Spectral Medical released its earnings results on Aug 07, 2026. The company reported €0 earnings per share for the quarter, beating the consensus estimate of -€0.006 by €0.006.

Is Spectral Medical overvalued?

According to Wall Street analysts Spectral Medical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Spectral Medical pay dividends?

Spectral Medical does not currently pay dividends.

What is Spectral Medical’s EPS estimate?

Spectral Medical’s EPS estimate is >-0.01.

How many shares outstanding does Spectral Medical have?

Spectral Medical has 293,554,000 shares outstanding.

What happened to Spectral Medical’s price movement after its last earnings report?

Spectral Medical reported an EPS of €0 in its last earnings report, beating expectations of -€0.006. Following the earnings report the stock price went down -1.765%.

Which hedge fund is a major shareholder of Spectral Medical?

Currently, no hedge funds are holding shares in DE:SD4

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Spectral Medical

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

Spectral Medical (SD4) Earnings & Revenues

Historic Earnings Reports

SD4 Stock 12 Month Forecast

Average Price Target

€2.17

▲(154.86% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","2":"€2","3":"€3","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.166318805,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€2.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.166318805,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€2.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.166318805,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.17</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.855,0.9558706773076923,1.0567413546153845,1.157612031923077,1.258482709230769,1.3593533865384615,1.4602240638461539,1.561094741153846,1.6619654184615384,1.7628360957692308,1.863706773076923,1.9645774503846154,2.065448127692308,{"y":2.166318805,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.855,0.9558706773076923,1.0567413546153845,1.157612031923077,1.258482709230769,1.3593533865384615,1.4602240638461539,1.561094741153846,1.6619654184615384,1.7628360957692308,1.863706773076923,1.9645774503846154,2.065448127692308,{"y":2.166318805,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.855,0.9558706773076923,1.0567413546153845,1.157612031923077,1.258482709230769,1.3593533865384615,1.4602240638461539,1.561094741153846,1.6619654184615384,1.7628360957692308,1.863706773076923,1.9645774503846154,2.065448127692308,{"y":2.166318805,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.51,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.915,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.885,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.925,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.805,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.795,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.795,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.845,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.815,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.855,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >